Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Epclusa

    - PMLiVE

    Gilead’s Yescarta shows benefits for patients with large B-cell lymphoma

    This is the most common type of non-Hodgkin lymphoma worldwide

    - PMLiVE

    Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

    The drug treatment is being evaluated in several ongoing phase 3 trials

    - PMLiVE

    AbbVie/Genmab’s lymphoma drug shows promise in phase 3 combination trial

    Follicular lymphoma affects around 15,000 people in the US every year

    - PMLiVE

    AbbVie shares promising phase 3 results for Rinvoq in severe alopecia areata

    Around 700,000 people in the US are living with some form of the autoimmune disease

    - PMLiVE

    AbbVie’s Elahere granted MHRA approval to treat platinum-resistant ovarian cancer

    Approximately 7,500 people are diagnosed with ovarian cancer every year in the UK

    - PMLiVE

    AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn

    ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma

    - PMLiVE

    AbbVie to expand immunology capabilities with $2.1bn Capstan acquisition

    The deal includes a CAR-T therapy in phase 1 development for B cell-mediated autoimmune diseases

    - PMLiVE

    AbbVie and ADARx enter multi-billion dollar partnership to develop siRNA therapies

    The companies will focus on developing therapeutics across neuroscience, immunology and oncology

    - PMLiVE

    AbbVie’s Emrelis granted FDA accelerated approval to treat advanced lung cancer

    An estimated 226,650 people will be diagnosed with lung cancer in the US this year

    - PMLiVE

    AbbVie’s JAK inhibitor Rinvoq granted FDA approval to treat giant cell arteritis

    The drug could allow patients to taper off steroids and achieve sustained remission

    - PMLiVE

    Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer

    Triple-negative breast cancer accounts for approximately 15% of all cases of the disease

    - PMLiVE

    AbbVie’s Rinvoq receives EC approval to treat adults with giant cell arteritis

    The drug is now the first oral JAK inhibitor to be approved in the EU for this patient population

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links